Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project-Reference-Cited by-同舟云学术

Lower HCV treatment uptake in women who have received opioid agonist therapy before and during the DAA era: The ANRS FANTASIO project

Published:2019-10 Issue: Volume:72 Page:61-68
ISSN:0955-3959
Container-title:International Journal of Drug Policy
language:en
Short-container-title:International Journal of Drug Policy

Author:

Rojas Rojas Teresa^ORCID,Di Beo Vincent,Delorme Jessica,Barre Tangui,Mathurin Philippe,Protopopescu Camelia,Bailly François,Coste Marion^ORCID,Authier Nicolas,Carrieri Maria Patrizia^ORCID,Rolland Benjamin,Marcellin Fabienne

Funder

French National Agency for Research on Aids and Viral Hepatitis

Publisher

Elsevier BV

Subject

Health Policy,Medicine (miscellaneous)

Reference66 articles.

1. Prescription opioid use, illicit drug use, and sexually transmitted infections among participants from a community engagement program in North Central Florida;Acheampong;Journal of Substance Use,2017

2. Recommandations AFEF pour l’élimination de l’infection par le virus de l’hépatite C en France;AFEF,2018

3. Access to hepatitis C virus treatment: Lessons from implementation of strategies for increasing access to antiretroviral treatment;Assefa;International Journal of Infectious Diseases: IJID,2018

4. LES ALD des bénéficiaires de la CMU-C. Points de repère;Assurance Maladie,2007

5. Comparative profiles of men and women with opioid dependence: Results from a national multisite effectiveness trial;Back;The American Journal of Drug and Alcohol Abuse,2011

Cited by 25 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Applying a stigma and time framework to facilitate equitable access to hepatitis C care among women who inject drugs: The ETHOS Engage Study;International Journal of Drug Policy;2024-07

2. Factors associated with hepatitis C testing, treatment, and current hepatitis C infection among men and women who inject drugs: The ETHOS engage study;International Journal of Drug Policy;2024-05

3. All-cause mortality before and after DAA availability among people living with HIV and HCV: An international comparison between 2010 and 2019;International Journal of Drug Policy;2024-02

4. Hepatitis C virus cure from direct‐acting antivirals and mortality: Are people with and without a history of injection drug use in the same boat? (ANRS CO22 Hepather cohort);Drug and Alcohol Review;2023-12-22

5. Impaired health-related quality of life in the HCV cure era: who is concerned? (ANRS CO22 HEPATHER French cohort);Quality of Life Research;2023-08-16